Global and India Meningococcal Disease Vaccine Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Meningococcal Disease Vaccine Market Report & Forecast 2024-2034
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
Market Analysis and InsightsGlobal and India Meningococcal Disease Vaccine Market
This report focuses on global and India Meningococcal Disease Vaccine market, also covers the segmentation data of other regions in regional level and county level.
The global Meningococcal Disease Vaccine revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the Meningococcal Disease Vaccine revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Meningococcal Disease Vaccine include AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. The global five biggest players hold a share of % in 2024.
Global Meningococcal Disease Vaccine Scope and Market Size
Meningococcal Disease Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Meningococcal Disease Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the Meningococcal Disease Vaccine market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.
AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Segment by Type
Polysaccharide
Conjugate
Combination
Infant
Child
Aldult
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Meningococcal Disease Vaccine definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Meningococcal Disease Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Meningococcal Disease Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and India Meningococcal Disease Vaccine Market
This report focuses on global and India Meningococcal Disease Vaccine market, also covers the segmentation data of other regions in regional level and county level.
The global Meningococcal Disease Vaccine revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the Meningococcal Disease Vaccine revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Meningococcal Disease Vaccine include AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. The global five biggest players hold a share of % in 2024.
Global Meningococcal Disease Vaccine Scope and Market Size
Meningococcal Disease Vaccine market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Meningococcal Disease Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the Meningococcal Disease Vaccine market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.
By Company
AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Segment by Type
Polysaccharide
Conjugate
Combination
Segment by Application
Infant
Child
Aldult
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Meningococcal Disease Vaccine definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Meningococcal Disease Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Meningococcal Disease Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Vaccine sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion